Search results for "present"

showing 10 items of 3598 documents

Abstract A004: Systemic RNA vaccines: Connecting effective cancer immunotherapy with antiviral defense mechanisms

2016

Abstract Mechanisms of antiviral host defense are important for survival and evolutionarily optimized for high sensitivity and potency. Intending to harvest the multitude of highly specialized and intertwined pathogen immune defense programs for cancer immunotherapy, we simulated a systemic pathogen intrusion into the blood stream by intravenous injection of lipid-formulated, tumor antigen-encoding mRNA nanoparticles. These RNA-lipoplexes (RNA-LPX) were directed to various lymphoid tissues, including the spleen, lymph nodes and bone marrow, which provide the ideal microenvironment for efficient priming and amplification of T cell responses. Solely the RNA-to-lipid ratio was discovered to de…

Cancer ResearchInnate immune systemmedicine.medical_treatmentT cellImmunologyTLR7Biologymedicine.anatomical_structureCancer immunotherapyAntigenImmunologymedicineCytotoxic T cellAntigen-presenting cellCD8Cancer Immunology Research
researchProduct

2004

Cancer ResearchInterleukin 21OncologyChemistryZAP70GeneticsCD28Cytotoxic T cellIL-2 receptorNatural killer T cellAntigen-presenting cellJurkat cellsCell biologyCancer Cell International
researchProduct

Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation.

2005

In humans as in other animal species, CD8+ cytotoxic T lymphocytes (CTLs) play an important if not the major role in controlling virus-infected and malignant cell growth. The interactions between CD8+ T cells and target cells are mediated by human leukocyte antigen (HLA) class I antigens loaded with viral and tumor antigen-derived peptides along with costimulatory receptor/ligand stimuli. Thus, to escape from CD8+ T-cell recognition and destruction, viruses and tumor cells have developed strategies to inhibit the expression and/or function of HLA class I antigens. In contrast, cells with downregulated MHC class I surface expression can be recognized by NK cells, although NK cell-mediated ly…

Cancer ResearchMacromolecular SubstancesDown-RegulationGenes MHC Class IHuman leukocyte antigenCD8-Positive T-LymphocytesNatural killer cellAntigenHLA AntigensNeoplasmsMHC class IViral InterferencemedicineCytotoxic T cellHumansAntigen-presenting cellbiologyMHC class I antigenAntigen processingmedicine.anatomical_structureOncologyVirus DiseasesImmunologybiology.proteinImmunotherapySignal TransductionInternational journal of cancer
researchProduct

The number of intratumoral dendritic cells and ?-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma

2001

BACKGROUND Dendritic cells (DCs) are antigen-presenting cells with a unique ability to cross prime T cells and generate strong antitumor responses. This study evaluates the presence and prognostic significance of DCs as well as functional T cells, which accumulate in the microenvironment in patients with oral squamous cell carcinoma (OSCC). METHODS Immunohistochemistry for S-100 positive or p55 positive DCs and for T-cell receptor (TcR)-associated ζ-chain expression in tumor-infiltrating lymphocytes (TILs) was performed in 132 paraffin embedded specimens from patients with primary OSCC. The median clinical follow-up for the patients was 50 months. The numbers of intratumoral DCs or TILs exp…

Cancer ResearchPathologymedicine.medical_specialtybusiness.industryCancerchemical and pharmacologic phenomenahemic and immune systemsDendritic cellmedicine.diseasemedicine.anatomical_structureOncologyEpidermoid carcinomaAntigenCarcinomamedicineAntigen-presenting cellbusinessLymph nodeSurvival analysisCancer
researchProduct

Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer.

2004

Several major histocompatibility complex (MHC) alleles have been reported to present peptides derived from the HPV16 E7 oncoprotein to T cells. We describe an overrepresentation of the HLA-B8 allele (28.44%) in cervical cancer patients as compared to the MHC class I allele frequency in a local healthy control population (18.80%) and the identification of an HLA-B8-binding peptide TLHEYMLDL (HPV16 E77–15), which is able to drive HPV16 E7-specific and MHC class I-restricted T-cell responses in peripheral blood lymphocytes from healthy individuals. TLHEYMLDLspecific T cells recognize the naturally processed and presented peptide on HPV16 cervical cancer cells transfected with the HLA-B8 gene d…

Cancer ResearchReceptors CCR7Time FactorsCD8 AntigensPapillomavirus E7 ProteinsT-LymphocytesCD1Genes MHC Class IUterine Cervical NeoplasmsBiologyMajor histocompatibility complexEpitopeHLA-B8 AntigenEpitopesMHC class ICytotoxic T cellHumansLymphocytesAntigen-presenting cellAllelesAntigen Presentationvirus diseasesOncogene Proteins ViralNatural killer T cellFlow CytometryMolecular biologyOncologyMicroscopy FluorescenceLymphatic MetastasisImmunologybiology.proteinLeukocyte Common AntigensFemaleReceptors ChemokineLymph NodesPeptidesCD8International journal of cancer
researchProduct

Generation of CD8+T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy

2015

Adoptive T-cell therapy of cancer often fails due to the tumor cells' immune escape mechanisms, like antigen loss or down-regulation. To anticipate immune escape by loss of a single antigen, it would be advantageous to equip T cells with multiple specificities. To study the possible interference of 2 T-cell receptors (TCRs) in one cell, and to examine how to counteract competing effects, we generated TETARs, CD8(+) T cells expressing two additional T-cell receptors by simultaneous transient transfection with 2 TCRs using RNA electroporation. The TETARs were equipped with one TCR specific for the common melanoma antigen gp100 and one TCR recognizing a patient-specific, individual mutation of…

Cancer ResearchSkin Neoplasmsmedicine.medical_treatmentReceptors Antigen T-CellCD8-Positive T-LymphocytesBiologyImmunotherapy AdoptiveAntigenCell Line TumormedicineHumansCytotoxic T cellPrecision MedicineAntigen-presenting cellReceptorMelanomaPharmacologyT-cell receptorImmunotherapyResearch PapersMolecular biologyOncologyCancer researchMolecular MedicineCytokine secretionChaperonin Containing TCP-1CD8gp100 Melanoma AntigenCancer Biology & Therapy
researchProduct

Regulation of CD1d expression by murine tumor cells: escape from immunosurveillance or alternate target molecules?

2002

alpha beta+ TCR T cells recognize peptide fragments displayed by MHC-class I or -class II molecules. Recently, additional mechanisms of antigen recognition by T cells have been identified, including CD1-mediated presentation of nonpeptide antigens. Only a limited number of CD1 antigens is retained in the mouse, i.e., the group II CD1 antigens, which are split into CD1D1 and CD1d2. Several T cell subsets have been shown to interact with murine CD1 antigens, including NK cells or "natural T cells" with the invariant V alpha 14 J alpha 281 TCR chain. Even if TAP defects may prevent classical endogenous antigen presentation in tumor cell lines, antigen presentation via CD1 is still functional. …

Cancer ResearchT cellAntigen presentationCD1chemical and pharmacologic phenomenaBiologyNatural killer cellAntigens CD1Immunoenzyme TechniquesInterferon-gammaMiceNK-92Monitoring ImmunologicmedicineCytotoxic T cellAnimalsRNA MessengerAntigen-presenting cellCells CulturedDNA PrimersMice Inbred BALB CReverse Transcriptase Polymerase Chain ReactionAntibodies MonoclonalGranulocyte-Macrophage Colony-Stimulating Factorhemic and immune systemsNeoplasms ExperimentalCytotoxicity Tests ImmunologicFlow CytometryCell biologyGene Expression Regulation NeoplasticKiller Cells NaturalMice Inbred C57BLmedicine.anatomical_structureOncologyCD1DImmunologybiology.proteinCytokinesAntigens CD1dInternational journal of cancer
researchProduct

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responsesin vitro

2006

Human tumors frequently escape immune destruction, despite the presence of cytotoxic T cells (CTL) recognizing tumor-associated antigens (TAA). We have previously shown that programmed death ligand-1 (PD-L1), a recently identified ligand of the B7 superfamily, is expressed on murine tumors and can inhibit antitumor immune responses. To evaluate the clinical relevance of our animal model findings, we examined human tumors and tumor-specific T cells. We found PD-L1 to be constitutively expressed on human renal cell carcinoma (RCC) cell lines and upregulated on human melanoma cell lines upon exposure to interferon-gamma. Similarly, we found binding of anti-PD-L1 monoclonal antibody (mAb) on fr…

Cancer ResearchT cellAntineoplastic AgentsB7-H1 AntigenInterleukin 21Immune systemAntigenAntigens CDTumor Cells CulturedmedicineHumansCytotoxic T cellCTLA-4 AntigenIL-2 receptorAntigen-presenting cellCarcinoma Renal CellMelanomabusiness.industryAntibodies MonoclonalFlow CytometryAntigens DifferentiationImmunohistochemistryKidney NeoplasmsUp-RegulationGene Expression Regulation Neoplasticmedicine.anatomical_structureOncologyImmunologyB7-1 AntigenCancer researchbusinessB7-H1 AntigenT-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man

2003

The human tyrosinase (hTyr) (369-377) cytotoxic T lymphocyte (CTL) epitope is presented by malignant melanoma and various nontransformed cells in association with human leukocyte antigen (HLA)-A*0201 (A2.1) and used for vaccination-based immunotherapy of melanoma patients. Its mouse homologue, mTyr (369-377), is naturally processed and bound by A2.1 with equivalent efficacy and thus enabled us to explore the effect of self tolerance on Tyr-specific T cells in different lines of A2.1 transgenic (Tg) mice and man. We found that self Tyr-reactive CTL in Tg mice and, importantly, in man were affected by partial tolerance resulting in only residual T lymphocytes of higher avidity for self Tyr al…

Cancer ResearchT-LymphocytesGenetic VectorsMice Transgenicchemical and pharmacologic phenomenaBiologyEpitopeImmune toleranceEpitopesMiceImmune systemAntigenAntigens CDAntigens NeoplasmHLA-A2 AntigenAnimalsHumansCytotoxic T cellCTLA-4 AntigenIL-2 receptorMelanomaAntigen PresentationHLA-A AntigensMonophenol MonooxygenaseVaccinationReceptors Interleukin-2hemic and immune systemsAntigens DifferentiationMolecular biologyPeptide FragmentsMice Inbred C57BLCTL*Self ToleranceOncologySelf ToleranceImmunologyImmunotherapyT-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma.

1997

Escape from immune surveillance is critical for tumor progression in metastatic melanoma. We assessed the function of melanoma-derived dendritic cells (DCs) in patients presenting simultaneously with responding (rM) or progressing (pM) melanoma metastases. These rare coincidences allowed us to compare syngeneically the function of tumor DCs. CD83+ DCs were purified freshly from large responding (rDCs) or progressing (pDCs) metastases following chemo-immunotherapy. rDCs were 5 times more potent inducers of allogeneic T-cell proliferation than the pDCs that were used as control. Phenotypic analysis showed a marked depression of CD86 expression on pDCs. Culture supernatants from pM showed prod…

Cancer ResearchT-LymphocytesImmune toleranceImmune systemAntigens CDAntigens NeoplasmAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAntigen-presenting cellMelanomaCD86Membrane Glycoproteinsbusiness.industryMelanomaInterferon-alphahemic and immune systemsDendritic cellDendritic Cellsmedicine.diseaseInterleukin-10Neoplasm ProteinsTolerance inductionOncologyTumor progressionImmunologyCytokinesInterleukin-2Tumor EscapeB7-2 AntigenCisplatinbusinessCell DivisionInternational journal of cancer
researchProduct